CTOs on the Move

Invivyd

www.invivyd.com

 
Invivyd is a biopharmaceutical company on a mission to rapidly and perpetually deliver antibody-based therapies that protect vulnerable people from the devastating consequences of circulating viral threats, beginning with SARS-CoV-2. ​​Invivyd`s technology works at the intersection of evolutionary virology, predictive modeling, and antibody engineering, and is designed to identify high-quality, long-lasting antibodies with the potential to resist viral escape. The company is generating a robust pipeline of product candidates which could be used in prevention or treatment of serious viral diseases, starting with COVID-19 and expanding into influenza and other high-need indications.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.invivyd.com
  • 1601 Trapelo Road Suite 178
    Waltham, MA USA 02451
  • Phone: 781.819.0080

Executives

Name Title Contact Details

Similar Companies

Kaiser Inc

Kaiser Inc is a Manteca, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aderans Research Institute

Aderans Research Institute is a Atlanta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caliper Life Sciences

Caliper Life Sciences is a Hopkinton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SyntheZyme

SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how

Sionna Therapeutics

We are a life sciences company that is building on over a decade of extensive research on the genetic mutations associated with cystic fibrosis.